{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:13:25Z","timestamp":1762866805381},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique & Fertilit\u00e9"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.gyobfe.2016.01.001","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T04:45:24Z","timestamp":1454474724000},"page":"106-112","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["L\u2019endom\u00e9triose est-elle une l\u00e9sion pr\u00e9-canc\u00e9reuse\u00a0? Perspectives et implications cliniques"],"prefix":"10.1016","volume":"44","author":[{"given":"G.","family":"Chene","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Caloone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Moret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Le Bail-Carval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Chabert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Beaufils","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mellier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lamblin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gyobfe.2016.01.001_bib0340","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0889-8545(05)70302-8","article-title":"Epidemiology of endometriosis","volume":"24","author":"Eskenazi","year":"1997","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0345","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.fertnstert.2006.06.015","article-title":"Economic burden of endometriosis","volume":"86","author":"Gao","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archsurg.1925.01120100007001","article-title":"Endometrial carcinoma of ovary arising in endometrial tissue in that organ","volume":"10","author":"Sampson","year":"1925","journal-title":"Arch Surg"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0670","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0360","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/639252","article-title":"Early preinvasive lesions in ovarian cancer","volume":"2014","author":"Chene","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0365","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0370","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijgo.2015.02.021","article-title":"The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis","volume":"130","author":"Chene","year":"2015","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"10.1016\/j.gyobfe.2016.01.001_bib0375","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.bpobgyn.2003.03.001","article-title":"Endometriosis and the development of malignant tumours of the pelvis. A review of literature","volume":"18","author":"Van Gorp","year":"2004","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0380","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1684\/bdc.2013.1785","article-title":"The fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma","volume":"100","author":"Chene","year":"2013","journal-title":"Bull Cancer"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0385","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(11)70404-1","article-title":"Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies","volume":"13","author":"Pearce","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0390","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ygyno.2005.11.033","article-title":"Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence","volume":"101","author":"Somigliana","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0395","first-page":"262","article-title":"Potential scenarios leading to ovarian cancer arising from endometriosis","volume":"213","author":"Kobayashi","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0400","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3892\/mmr.2014.2057","article-title":"Understanding the role of epigenomic, genomic and genetic alterations in the development of endometriosis","volume":"9","author":"Kobayashi","year":"2014","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0405","first-page":"283","article-title":"Malignant changes in endometriosis","volume":"2","author":"Scott","year":"1953","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0410","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1525-1438.2007.00822.x","article-title":"Malignant degeneration of perineal endometriosis in episiotomy scar, case report and review of the literature","volume":"17","author":"Chene","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0415","first-page":"318","article-title":"A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes","volume":"53","author":"Czernobilsky","year":"1979","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0420","first-page":"642","article-title":"Loss of ARID1A\/BAF 250a expression in ovarian endometriosis and clear cell carcinoma","volume":"5","author":"Xiao","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0425","first-page":"1","article-title":"Loss od ARID1A\/BAF 250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?","author":"Samartzis","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0430","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/emboj.2010.27","article-title":"A cooperative activation loop among SWI\/SNF, H2AX, and H3\u00a0acetylation for DNA double-strand break repair","volume":"29","author":"Lee","year":"2010","journal-title":"EMBO J"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0435","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/IGC.0b013e318231f140","article-title":"Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers","volume":"22","author":"Lowery","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0445","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1097\/IGC.0b013e31826b5dcc","article-title":"Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma","volume":"22","author":"Ayhan","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0450","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/his.12721","article-title":"ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component","volume":"67","author":"Nishikimi","year":"2015","journal-title":"Histopathology"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0455","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/modpathol.2011.189","article-title":"Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations","volume":"25","author":"Yamamoto","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0460","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00428-011-1169-8","article-title":"PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma","volume":"460","author":"Yamamoto","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0465","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/path.2940","article-title":"PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma","volume":"225","author":"Yamamoto","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0470","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.humpath.2006.10.007","article-title":"Alternate molecular genetic pathways in ovarian carcinomas of common histological types","volume":"38","author":"Willner","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0475","doi-asserted-by":"crossref","first-page":"18824","DOI":"10.3390\/ijms140918824","article-title":"ARID1A mutations and PI3K\/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas","volume":"14","author":"Samartzis","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0480","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/modpathol.2013.216","article-title":"Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217\u00a0amplification in ovarian clear cell carcinoma","volume":"27","author":"Huang","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0485","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/bjc.2013.126","article-title":"New perspectives on molecular targeted therapy in ovarian clear cell carcinoma","volume":"108","author":"Tan","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0490","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1172\/JCI59309","article-title":"An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice","volume":"122","author":"Kinross","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0495","first-page":"7052","article-title":"Loss of heterozygosity on 10q23.3\u00a0and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary","volume":"60","author":"Sato","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0500","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jjco\/hyu221","article-title":"Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy","volume":"45","author":"Yamashita","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0505","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/modpathol.2011.143","article-title":"Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas","volume":"25","author":"Yamamoto","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0510","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/modpathol.2011.70","article-title":"Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient","volume":"24","author":"Yamamoto","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0515","doi-asserted-by":"crossref","first-page":"e57724","DOI":"10.1371\/journal.pone.0057724","article-title":"Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis","volume":"8","author":"Yamashita","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0520","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/br.2012.19","article-title":"Hepatocyte nuclear factor (HNF)-1\u03b2 and its physiological importance in endometriosis","volume":"1","author":"Akasaka","year":"2013","journal-title":"Biomed Rep"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0525","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jcma.2013.07.008","article-title":"Ovarian cancers arising from endometriosis: a microenvironmental biomarker study including ER, HNF1\u00df, p53, PTEN, BAF250a, and COX-2","volume":"76","author":"Lai","year":"2013","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0530","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/mc.22072","article-title":"Hepatocyte nuclear factor-1\u03b2 (HNF-1\u03b2) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma","volume":"54","author":"Okamoto","year":"2015","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0535","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3892\/ol.2013.1550","article-title":"Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (review)","volume":"6","author":"Uekuri","year":"2013","journal-title":"Oncol Lett"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0540","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0545","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/path.4516","article-title":"Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden","volume":"236","author":"Anglesio","year":"2015","journal-title":"J Pathol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0550","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45\u00a0epidemiological studies including 23,257\u00a0women with ovarian cancer and 87,303\u00a0controls","volume":"371","author":"Collaborative Group on Epidemiological Studies of Ovarian Cancer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0555","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/humrep\/der211","article-title":"The \u201cincessant menstruation\u201d hypothesis: a mechanistic ovarian cancer model with implications for prevention","volume":"26","author":"Vercellini","year":"2011","journal-title":"Hum Reprod"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0560","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes\u2013the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0565","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ncponc0558","article-title":"Mechanisms of disease: oncogene addiction\u00a0\u2013\u00a0a rationale for molecular targeting in cancer therapy","volume":"3","author":"Weinstein","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0570","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1158\/0008-5472.CAN-12-4593","article-title":"A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1","volume":"73","author":"Oike","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0575","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2174\/156800908786733504","article-title":"The PIK3CA gene as a mutated target for cancer therapy","volume":"8","author":"Gustin","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0580","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3892\/or.2014.3268","article-title":"The PI3K\/mTOR dual inhibitor NVP-BEZ235\u00a0reduces the growth of ovarian clear cell carcinoma","volume":"32","author":"Oishi","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0585","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1158\/1078-0432.CCR-09-0365","article-title":"mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary","volume":"15","author":"Mabuchi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0590","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0595","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","article-title":"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206\u00a0in patients with advanced solid tumors","volume":"29","author":"Yap","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0600","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1073\/pnas.0508776103","article-title":"Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752","volume":"103","author":"Smolen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0605","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1525-1438.2007.01135.x","article-title":"Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274\u00a0on human ovarian carcinoma cell growth, motility, and invasion","volume":"18","author":"Koon","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/neo.09948","article-title":"An orally available small molecule inhibitor of c-MET, PF 2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis","volume":"12","author":"Zillhardt","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0615","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1186\/1471-2407-14-831","article-title":"An increased risk of epithelial ovarian cancer in Taiwanese women with a new surgico-pathological diagnosis of endometriosis","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0620","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejogrb.2007.06.017","article-title":"Ovarian endometrioma\u2013risks factors of ovarian cancer development","volume":"138","author":"Kobayashi","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0625","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jmig.2012.11.010","article-title":"Surgical implications of the potential new tubal pathway for the ovarian carcinogenesis","volume":"20","author":"Chene","year":"2013","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0630","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ije\/dyt042","article-title":"Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies","volume":"42","author":"Sieh","year":"2013","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0635","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/humupd\/dmq030","article-title":"Tubal ligation and the risk of ovarian cancer: review and meta-analysis","volume":"17","author":"Cibula","year":"2011","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0640","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.critrevonc.2013.03.004","article-title":"Tube or note tube: that is the question\u2026 About serous ovarian carcinogenesis","volume":"88","author":"Chene","year":"2013","journal-title":"Croit Rave Oncol Hematol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0645","doi-asserted-by":"crossref","first-page":"471.e1","DOI":"10.1016\/j.ajog.2014.01.003","article-title":"Ovarian Cancer Research Program of British Columbia. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention","volume":"210","author":"McAlpine","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0650","first-page":"292","article-title":"Incessant ovulation and ovarian cancer - a hypothesis re-visited","volume":"5","author":"Fathalla","year":"2013","journal-title":"Facts Views Vis Obgyn"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0655","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1600-0412.2011.01114.x","article-title":"Underlying mechanisms of ovarian cancer risk reduction after tubal ligation","volume":"90","author":"Cibula","year":"2011","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0660","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/AOG.0b013e318212fcb7","article-title":"Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy","volume":"117","author":"Vitonis","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0665","first-page":"1183","article-title":"Urinary, infectious and digestive events related to benign hysterectomy and the associated surgery on the fallopian tube: guidelines","volume":"44","author":"Chene","year":"2015","journal-title":"J Gynecol Obstet Biol Reprod"},{"key":"10.1016\/j.gyobfe.2016.01.001_bib0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.03.044","article-title":"New insights in the pathophysiology of ovarian cancer and implications for screening and prevention","author":"Nezhat","year":"2015","journal-title":"Am J Obstet Gynecol"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique & Fertilit\u00e9"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297958916000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297958916000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T06:53:08Z","timestamp":1567579988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297958916000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1297958916000023"],"URL":"https:\/\/doi.org\/10.1016\/j.gyobfe.2016.01.001","relation":{},"ISSN":["1297-9589"],"issn-type":[{"value":"1297-9589","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L\u2019endom\u00e9triose est-elle une l\u00e9sion pr\u00e9-canc\u00e9reuse\u00a0? Perspectives et implications cliniques","name":"articletitle","label":"Article Title"},{"value":"Gyn\u00e9cologie Obst\u00e9trique & Fertilit\u00e9","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gyobfe.2016.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}